Overexpression Of Muts Alpha Complex Proteins Predicts Poor Prognosis In Oral Squamous Cell Carcinoma by Wagner et al.
icine®
ONAL STUDYMed
OBSERVATIOverexpression of MutSa Complex Proteins Predicts Poor
Prognosis in Oral Squamous Cell Carcinoma
Vivian Petersen Wagner, DDS, Liana Preto Webber, DDS, MS, Gabriela Salvadori, DDS,
DDS, PhD, Roge´rio M o, DDS, PhD,
D,Luise Meurer, MD, PhD, Felipe Paiva Fonseca,
Cristiane Helena Squarize, DDS, Phue
variable analysis, high expression of the MutSa complex was an
independent prognostic factor for poor overall survival (hazard ratio:
2.75, P¼ 0.02).
unknown. In esophag
et al7 found that the
expression of hMLH1
Editor: Yufang Ma.
Received: January 16, 2016; revised: April 6, 2016; accepted: April 19,
2016.
From the Department of Oral Pathology, School of Dentistry, Universidade
Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
(VPW, LPW, MDM); Experimental Pathology Unit, Hospital de Clı´nicas
de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil (VPW, LPW,
LM, MDM); Institute of Oral Biology, Faculty of Dentistry, University of
Oslo, Norway (GS); Department of Oral Diagnosis, Piracicaba Dental
School, University of Campinas, Piracicaba, Sa˜o Paulo, Brazil (FPF, PAV);
and Laboratory of Epithelial Biology, Department of Periodontics and Oral
Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI
(RMC, CHS).
Correspondence: Manoela Domingues Martins, Faculdade de Odontologia,
Universidade Federal do Rio Grande do Sul Rua Ramiro Barcelos,
2492, sala 503, CEP 90035–003, Santana, Porto Alegre RS, Brazil
(e-mail: manomartins@gmail.com).
LM, PAV, and MDM are research fellows funded by the Brazilian National
Council for Scientific and Technological Development (CNPq). This
study was supported by the Postgraduate Research Group of the Porto
Alegre University Hospital (GPPG/FIPE: 15–0210).
All authors state they have no potential conflicts of interest to declare.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution-NonCommercial-NoDerivatives License 4.0, where it is
permissible to download, share and reproduce the work in any medium,
provided it is properly cited. The work cannot be changed in any way or
used commercially.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000003725
Medicine  Volume 95, Number 22, June 2016oraes Castilh
gas, DDS, PhDand Manoela Doming
Abstract: The DNAmismatch repair (MMR) system is responsible for
the detection and correction of errors created during DNA replication,
thereby avoiding the incorporation of mutations in dividing cells. The
prognostic value of alterations in MMR system has not previously been
analyzed in oral squamous cell carcinoma (OSCC).
The study comprised 115 cases of OSCC diagnosed between 1996
and 2010. The specimens collected were constructed into tissue micro-
array blocks. Immunohistochemical staining for MutSa complex
proteins hMSH2 and hMSH6 was performed. The slides were sub-
sequently scanned into high-resolution images, and nuclear staining of
hMSH2 and hMSH6 was analyzed using the Nuclear V9 algorithm.
Univariable and multivariable Cox proportional hazard regression
models were performed to evaluate the prognostic value of hMSH2
and hMSH6 in OSCC.
All cases in the present cohort were positive for hMSH2 and hMSH6
and a direct correlation was found between the expression of the
proteins (P< 0.05). The mean number of positive cells for hMSH2
and hMSH6 was 64.44 15.21 and 31.46 22.38, respectively. These
values were used as cutoff points to determine high protein expression.
Cases with high expression of both proteins simultaneously were
classified as having high MutSa complex expression. In the multi-Pablo Agustin Var ,
s Martins, DDS, PhD
This study provides a first insight of the prognostic value of
alterations in MMR system in OSCC. We found that MutSa complex
may constitute a molecular marker for the poor prognosis of OSCC.
(Medicine 95(22):e3725)
Abbreviations: HNPCC = hereditary nonpolyposis colon cancer,
MMR = DNA mismatch repair, OSCC = oral squamous cell
carcinoma, SD = standard deviation, TMA = tissue microarray.
INTRODUCTION
T he multistep process of oral carcinogenesis depends on theaccumulation of genetic and epigenetic alterations, leading
to genomic instability, cellular transformation, and tumor pro-
gression.1 The DNA damage repair mechanisms are responsible
for the maintenance of genome integrity.2 Germline mutations
of DNA damage repair genes as well as the epigenetic-driven
loss of function result in the enhanced incorporation of
mutations and, consequently, genomic instability. The DNA
mismatch repair (MMR) system is responsible for the detection
and correction of errors created during DNA replication,
thereby avoiding the incorporation of mutations in dividing
cells. This pathway eliminates severely damaged and genomi-
cally instable cells and thereby plays as important role in the
prevention of short-term mutagenesis and long-term tumorigen-
esis.2,3
The DNA MMR system is composed of 3 related, yet
distinct, proteins subunits: MutSa (hMSH2þhMSH6), MutSb
(hMSH2þhMSH3), and MutLa (hMLH1þhPMS2). The
MutSa complex is continuously expressed during all phases
of the cell cycle and is capable of movement along the contours
of homoduplex DNA. hMSH2 and hMSH6 are required in the
initiation of the MMR pathway. Moreover, the MutSa complex
can interact with many downstream proteins involved in
induced cell cycle arrest, apoptosis, chromatin remodeling,
and other DNA repair pathways.4 The MMR system has been
widely studied in the past decade due to its association with
several diseases and conditions, including hereditary nonpoly-
posis colon cancer (HNPCC).5 More recently, an increased
number of cancers have been associated with defects in the
MMR mechanism, including colon, endometrium, and prostate
cancer.6,7
Previous studies have suggested the loss of expression of
MMR-related proteins, especially hMLH1, during the process
of oral carcinogenesis.8–15 However, most of these studies
focused on potentially malignant oral disorders. Moreover,
the prognostic value of MMR proteins in OSCC remainseal squamous cell carcinoma, Uehara
absence of the immunohistochemical
and hMSH2 was associated with poor
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survival rates. Recently, hMSH6 overexpression has been
shown to be associated with a poor prognosis in cases of
melanoma16 and osteosarcoma17 and correlated to tumor pro-
gression during chemotherapy in malignant pleural mesothe-
lioma.18
Current literature provides some insights regarding the role
of theMMR system in oral carcinogenesis. However the clinical
significance of these phenomena remains unclear. To the best of
our knowledge, there are no data regarding the possible prog-
nostic value of MMR proteins for cases of OSCC. Moreover,
hMSH6 expression has never been evaluated in OSCC, yet both
hMSH2 and hMSH6 are required for the initiation of the MMR
pathway. Thus, the aim of the present study was to access the
value ofMutSa complex proteins hMSH2 and hMSH6 in OSCC
and correlate the findings with clinical-pathological aspects and
overall survival rates.
METHODS
Study Population
One hundred fifteen stored tissue blocks of OSCC diag-
nosed between 1996 and 2010 by the Pathology Laboratory of
the Porto Alegre University Hospital in Brazil were included in
this retrospective study (Human Research Ethics Committee
approval: 49942215.2.0000.5327). Cases with a histopatholo-
gical diagnosis of OSSC on the tongue, floor of the mouth, lip,
buccal mucosa, and palate were randomly selected. The medical
records were manually evaluated and data were collected on
demographic characteristics, risk factors, clinical presentation,
treatment, and outcomes. Pack-years of smoking were calcu-
lated using the following formula: ([mean number of cigarettes
smoked per day/20] number of years smoked). The follow-up
period was defined as the date of diagnosis until the last visit to
the hospital or date of death. Only cases with at least 70% of
complete information in the medical records and an adequate
amount of material for the analysis of specimens were included.
Histological sections were graded based on the criteria
described by Bryne et al.19
Tissue Microarray Construction
The specimens retrospectively collected were constructed
into tissue microarray (TMA) blocks for immunohistochemical
analysis. TMA construction was performed as described else-
where.20 Briefly, tumor areas of the invasive front of the tumor
were selected and marked on hematoxylin-eosin-stained sec-
tions using an objective marker (Nikon Corp, Tokyo, Japan).
The slide was then overlaid on the original paraffin block to
determine the corresponding area to be used. A manual tissue
arrayer (Sakura Co, Japan) was used and 3 representative
cylindrical cores from the invasive front measuring 2.0 mm
in diameter were taken from each tissue block of OSCC and
arranged sequentially in a ready-to-use recipient paraffin block
(Sakura Co, Japan). Three cores of normal mucosa were
inserted in the left upper corner of each recipient block for
orientation. A map specifying the exact position of each case
was prepared to facilitate the interpretation of the
immunohistochemical results.
Immunohistochemistry
For immunohistochemical staining, the samples were sec-
Wagner et altioned into 3-mm sections and placed on silanized slides. The
slides were de-paraffinized in xylene and hydrated in descend-
ing grades of ethanol. Antigen retrieval was performed prior to
2 | www.md-journal.comincubation of the primary antibodies. The primary antibodies,
sources, clone, antigen retrieval, dilutions, and incubation times
were as follows: hMSH2 (Santa Cruz, polyclonal, low pH
solution in a water bath at 908C for 18 h, 1:100, 18 h) and
hMSH6 (Cell Marque, 44, low pH solution in a water bath at
908C for 18 h, 1:50, 18 h). The sections were then incubated
with diaminobenzidine tetrahydrochloride (DAB, Novocastra,
Newcastle, UK) and counterstained with Mayer’s hematoxylin.
Negative controls were obtained by replacing the primary
antibodies with nonimmune serum. The positive control used
for both proteins was benign colonic tissue.
Digital Analysis
The immunohistochemical slides were subsequently
scanned into high-resolution images using the Aperio Scan-
scope CS Slide Scanner (Aperio Technologies Inc, Vista, CA).
All digital images obtained in .svs format were visualized using
the ImageScope software (Aperio Technologies Inc., Vista,
CA). MSH2 and MSH6 nuclear staining was analyzed using
the Nuclear V9 algorithm (Aperio Technologies Inc, Vista, CA)
with the following input parameters: averaging radius: 0.9;
curvature threshold: 2.5; lower threshold: 0; upper threshold:
230; minimum nuclear size: 22; maximum nuclear size: 165;
minimum roundness: 0.3; minimum compactness: 0.1; mini-
mum elongation: 0.2; clear area objective: 240; and an
intensity threshold ranging from 0 to 230, in which strong
staining was considered from 0 to 185 and weak staining
was from 185 to 230. At least 1000 cells were quantified in
10 hotspot areas of each case and the percentage of positive cells
was determined.
Statistical Analysis
All clinical and immunohistochemical data were analyzed
with the aid of the SPSS (IBM Corporation, Armonk, NY),
version 18.0. Differences between groups were evaluated using
the Mann-Whitney test. Spearman’s correlation coefficients
were calculated to determine the correlation of hMSH2 and
hMSH6 expression. Univariable and multivariable Cox pro-
portional hazard regression models were performed to evaluate
poor prognosis predictors in OSCC. The assumption of pro-
portional hazards was verified for all variables entering the
model. Independent variables with P< 0.25 in univariable
models were incorporated into the multivariable model. The
stepwise backward method was used to achieve a final model
and maintenance of variables was determined by P< 0.10.
Kaplan-Meier cumulative survival curves were constructed.
For all tests, a P< 0.05 was considered indicative of
statistical significance.
RESULTS
Cohort of OSCC Patients Used in Study
A cohort of 115 patients derived from the Porto Alegre
University Hospital in Brazil was used in this study (Table 1).
The majority of the patients were Caucasian (92.1%) compared
to black and non-otherwise specified patients. The proportion of
males was higher (87%) in comparison to females. The majority
of the patients had history of smoking, with over 60% of the
population current smokers, while 13.9% were former smokers.
Nonsmokers represented a smaller proportion (11.3%). The
Medicine  Volume 95, Number 22, June 2016majority of patients were diagnosed in an advanced clinical
stage (65.2%). The tumors were graded in histopathological
grades II and III in over 70% of patients. The follow-up period
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinical-Pathological Aspects of Patients With OSCC
Demographic/Clinical Characteristics OSCC (n¼ 115)
Age 60.89 (10.80)
Gender
Male 100 (87%)
Female 15 (13%)
Ethnicity
Caucasian 106 (92.1%)
Black 8 (7%)
Missing 1 (0.9%)
Residence
Urban 96 (83.5%)
Rural 17 (14.8%)
Missing 2 (1.7%)
Tobacco habits
User 70 (60.9%)
Former user 16 (13.9%)
Non-user 13 (11.3%)
Missing 16 (13.9%)
Pack-years 39.19 (23.90)
Clinical aspects
Ulcer 93 (79.9%)
Spot/plaque/nodule 10 (9.7%)
Missing 12 (10.4%)
Pain
Yes 70 (60.9%)
No 26 (22.6%)
Missing 19 (16.5)
Size
T1/T2 40 (34.8%)
T3/T4 67 (58.3%)
Missing 8 (7%)
Nodal metastasis
Yes 56 (48.7%)
No 53 (46.1%)
Missing 6 (5.2%)
TNM
I/II 34 (29.6%)
III/IV 75 (65.2%)
Missing 6 (5.2%)
Recurrence
Yes 38 (33%)
No 73 (63.5%)
Missing 4 (3.5%)
Histopathological grade

Grade I 32 (27.8%)
Grade II/III 83 (72.2%)
Evolution
Living 79 (68.7%)
Deceased 33 (28.7%)
Missing 3 (2.6%)
OSCC¼ oral squamous cell carcinoma.
Medicine  Volume 95, Number 22, June 2016ranged from 1 to 140 months (mean standard deviation (SD):
43.21 35.85). During follow-up, 33% of patients presented

According to Bryne et al.19recurrence, with a meanSD time to recurrence of
19.44 14.40 months and 29.5% of patients (n¼ 33) deceased
because of the tumor or associated causes.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Active MutSa Complex in OSCC
All cases included in the analysis presented positive cells
for both hMSH2 and hMSH6 (Figure 1A). The mean number of
positive cells for hMSH2 and hMSH6 was 64.44 15.21 and
31.46 22.38, respectively. The means were used as the cutoff
points to determine low and high expression of hMSH2 and
hMSH6 (Figure 1B and C). High hMSH2 and hMSH6 expres-
sion was found in 47 (59.1%) and 61 (46.5%) cases, respect-
ively. Thirty-two cases (27.8%) exhibited high hMSH2 and
hMSH6 expression simultaneously. These cases were classified
as exhibiting high MutSa expression. Figure 2 and Table 2
displays the expression of hMSH2 and hMSH6 according to the
main clinical-pathological aspects. Both proteins demonstrated
homogenous distribution regarding tobacco habits, presence of
nodal metastasis, clinical stage, recurrence, and histopatholo-
gical grade. An association was found between hMSH2 expres-
sion and tumor size, in which tumors with a higher T status (T3/
T4) had lower hMHS2 expression (P¼ 0.03, Mann-Whitney
test).
Direct Correlation Between hMSH2 and hMSH6
Expression
Once we found that all tumors from the 115 patients were
positive for hMSH2 and hMSH6, we decided to determine
whether the both markers were correlated. Indeed, we found
that hMSH2 expression levels in OSCC were significantly
correlated with the levels of hMSH6, as demonstrated by the
Spearman correlation coefficient of 0.38 (P< 0.05) (Figure 3).
Higher Expression of the MutSa Complex As a
Predictive Factor of Poor Prognosis in OSCC
The univariable analysis revealed that the presence of pain
at diagnosis, a higher T status (T3/T4), advanced clinical stage
(TNM III/IV), recurrence, higher degrees of malignancy
(Bryne’s grade II/III), hMSH6 and hMutSa overexpression
were associated with poor survival rates (Table 3). Recurrence,
clinical stage, and MutSa overexpression remained signifi-
cantly associated with poor survival rates in the multivariable
analysis. The Kaplan-Meier overall survival curve demon-
strated that the first 25 months after diagnosis were associated
with the most pronounced decline in cumulative survival
(Figure 4A). Patients with MutSa overexpression had poor
survival rates during the follow-up period in comparison to
patients with lower MutSa expression (Figure 4B).
DISCUSSION
In recent decades, no absolute gain has been achieved in
OSCC survival rates,21 and this tumor remains responsible for
more than 120,000 deaths per year worldwide.22 Alterations in
the MMR system have previously been described in potentially
malignant oral disorders and OSCC.8–15 However, the prog-
nostic value of these alterations has not previously been ana-
lyzed. In the present study, immunohistochemical analysis of
MutSa complex proteins hMSH2 and hMSH6 was performed
for 115 cases of OSCC. Our main finding revealed that MutSa
complex overexpression was associated with poor overall sur-
vival in patients with OSCC.
The DNA MMR system corrects base mismatches that
occur during replication.2 TheMutSa complex is composed of 1
MutSa Complex in Oral Squamous Cell Carcinomamolecule of hMSH2 and 1molecule of hMSH6 and is capable of
recognizing base/base mismatches and short insertion/deletion
loops.4 In the early 1990s, defects in the MMR system were
www.md-journal.com | 3
FIGURE 1. MutSa complex expression in OSCC. A, Representative examples of hMSH2 and hMSH6 expression in OSCC. hMSH2 and
hMSH6 presented nuclear staining in tumor cells. Note that in low expression cases, staining was restricted in the periphery of tumor
nou
the
h e
Wagner et al Medicine  Volume 95, Number 22, June 2016shown to be associated with HNPCC and some sporadic cases of
colon cancer.5 Indeed, malfunction of the MMR system is
associated with decreased genomic stability, which can cause
high rates of mutations throughout the genome.6 Since the first
reports of the involvement of the MMR system in colon cancer,
several studies have been conducted to evaluate the role of this
system in different types of cancer. In OSCC, however, the role
of MMR remains unclear. Previous studies have demonstrated
that hMLH1 expression is inversely associated with OSCC
differentiation15 and with the degree of dysplasia in oral leu-
koplakia.8 Furthermore, hMLH1 and hMSH2 expression
decrease throughout the process of lip carcinogenesis.11 These
previous data suggest that MMR deficiency is associated with
the progression of oral carcinogenesis and more aggressive
islands ( ), whereas in high expression cases, staining was homoge
(C) hMSH6 demonstrating the distributing of proteins expression in
line) was used as a cutoff point to determine cases of low and higtumors. However, the association between these markers and
overall survival of OSCC had never been analyzed. Thus, the
clinical significance of these events remained unclear. In the
4 | www.md-journal.compresent study, patients with higher expression of hMSH6
demonstrated poor survival rates. Moreover, the MutSa com-
plex overexpression was an independent prognostic aspect in
the multivariate analysis. Besides MutSa complex, TNM and
recurrence were independent prognostic factors of the present
study; however, it is important to note that the ratio between
sample size and number of events represents a limitation of the
present study.
Recently, MMR deficiency has been indicated to be a
marker of good prognosis in different solid tumors. Kato et al23
demonstrated that MMR-deficient endometrial cancer cases had
significantly better progression-free and overall survival com-
pared with MMR-retained cases. Moreover, high hMSH6
expression is associated with an increased risk of death from
sly distributed throughout the tumor. Box plots of (B) hMSH2 and
presentOSCC cohort. For each protein, themain value (horizontal
xpression. OSCC¼oral squamous cell carcinoma.a primary melanoma16 and, combined with hMSH2 expression,
is associated with shorter survival times and presence of
metastasis in patients with osteosarcoma.17 High hMSH6
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
clinical-pathological aspects. Note very homogenous distribution in
l metastasis, clinical stage, recurrence, and histopathological grade. In
ower hMHS2 expression (P¼0.03, Mann-Whitney test).
Medicine  Volume 95, Number 22, June 2016 MutSa Complex in Oral Squamous Cell Carcinomaexpression has also been associated with a nonresponse to
chemotherapy in patients with osteosarcoma17 and malignant
pleural mesothelioma.18 Therefore, the present results are in
agreement with these previous reports and lend support to the
notion that the activation of the MutSa complex is associated
with more aggressive tumors and can be used as a prognostic
marker for different solid tumors, including OSCC.
In the present study, higher hMSH6 expression was associ-
ated with poor prognosis, whereas hMSH2 expression was not.
Nevertheless, the analysis of both proteins combined (MutSa
complex) revealed a significant association between aMutSa
complex overexpression with poor prognosis. Furthermore,
hMSH2 and hMSH6 were directly correlated, which demon-
strates that an increase in hMSH2 is correlated with an increase
in hMSH6. The complex formation between hMHS2 and
hMSH6 appears to be extremely important. Previous reports
have demonstrated that hMSH2 fails to relocate to the nucleus
in cells that lack hMSH6.24 Moreover, both hMSH2 and
hMSH6 are required for initiation of the MMR pathway. Thus,
analyzing the simultaneous overexpression of both proteins
is important to greater precision in the evaluation of
MMR activation.
The MutSa complex is regulated by both endogenous
stimuli, such as the cell cycle, and exogenous stimuli. hMSH2
FIGURE 2. Box plots of hMSH2 and hMSH6 according to the main
the expression of both proteins with regard to tobacco habits, noda
relation to tumor size, patients with higher T status (T3/T4) had llevels increase at least 12-fold in proliferating cells in com-
parison to resting cells.25 Expression levels of this protein
increase during replicative and postreplicative phases of the
FIGURE 3. Direct correlation between hMSH2 and hMSH6 (scat-
ter plot). Note that an increase in hMSH2 was correlated with an
increase in hMSH6 (Spearman correlation coefficient: 0.38;
P<0.05).
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TABLE 2. Association Between hMSH2 and hMSH6 Expres-
sion and Clinical-Pathological Aspects
hMSH2 P hMSH6 P
Tobacco habits
No 62.75 (12.04) 0.39 25.85 (17.06) 0.56
User/former user 64.99 (15.90) 32.00 (22.67)
Size
T1/T2 68.48 (10.99) 0.03 29.30 (18.34) 0.67
T3/T4 61.79 (16.89) 32.81 (24.16)
Nodal metastasis
Yes 64.44 (16.99) 0.55 33.18 (24.36) 0.54
No 64.39 (12.47) 29.64 (19.89)
Clinical Stage
I/II 63.03 (15.46) 0.58 24.89 (18.86) 0.07
III/IV 65.02 (14.91) 33.86 (23.12)
Recurrence
Yes 64.10 (12.95) 0.74 28.77 (20.77) 0.45
No 64.49 (16.62) 32.77 (23.72)
Histopathologic
graduation
Grade I 63.87 (12.66) 0.56 27.66 (20.08) 0.35
Grade II/III 64.66 (16.11) 32.95 (23.17)
Evolution
Life 64.46 (15.86) 0.79 28.81 (20.27) 0.24
Dead 64.25 (14.40) 36.09 (26.70)
FIGURE 4. Kaplan-Meier analysis of (A) OSCC patient overall
survival and (B) according to MutSa expression. Patients with
higher expression of MutSa presented more pronounced decline
in the survival curve compared with patients with lower MutSa
Wagner et al Medicine  Volume 95, Number 22, June 2016cell cycle. Interestingly, MSH2 levels decrease 4-fold when
cells are induced to differentiation.25 Besides endogenous
stimuli, mutagenic treatments, such as alkylating agents,
increase the levels of hMSH2 and hMSH6, resulting from
the translocation of the complex from the cytoplasm to the
nucleus. This inducible response occurs immediately after
alkylation and is both long-lasting and dose-dependent.26
The intracellular location of MMR proteins is crucial, as these
proteins need to be in the nucleus to repair DNA.24 These
previous data lend support to the notion that the activation of
MutSa complex occurs in undifferentiated cells, with a higher
proliferative profile and under mutagenic stimuli. Therefore,
these cells must have a more aggressive pattern. This could
explain the results of the present study, which demonstrated that
MutSa complex overexpression is an independent prognostic
factor for poor overall survival in patients with OSCC.
Recently, the development of the Next-Generation Sequen-
cing has significantly improved the discovery of single-base
changes, providing a novel perspective for several diseases,27
including OSCC.28,29 Among all 106 cases analyzed in both
studies cited, only 1 case exhibited hMSH6 mutation.28
Mutations in other genes involved in DNA repair, such as
MYH1, LIG3, BRCA2, and POLD1, have been identified in
some cases.28 From this data, one may presume that the MMR
system is not mutated and is functional in OSCC. Moreover,
functional inactivation ofMMRgenes is associated with a lack of
protein expression.7 Therefore, the present findings, which
demonstrated that all cases of OSCC in the cohort analyzed
exhibited the immunohistochemical expression of hMSH2 and
Mann-Whitney test.hMSH6, corroborate the assumption that the MMR system is
functional in OSCC. The present results also demonstrate that the
cases with greater expression of MutSa have poor survival rates.
6 | www.md-journal.comThis higher expression may indicate an increased activation of
this pathway induced by genomic instability. We assume that the
MMR pathway in OSCC is not sufficient to induce cell death,
presumably due to the lack of function of key genes, such as p53,
which is known to be highly mutated in OSCC.
Although future studies are necessary to clarify the role of
the MMR system in OSCC, the MutSa complex may constitute
expression in the first year after diagnosis (12-months) and also in
a later period (after 50-months) (Log rank test, P¼0.03).
OSCC¼oral squamous cell carcinoma.a molecular marker for poor prognosis in patients with OSCC.
The cutoff values for hMSH2 and hMSH6 proposed in the
present study need to be validated in larger studies.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
12. Nunn J, Nagini S, Risk JM, et al. Allelic imbalance at the DNA
TABLE 3. Predictors of Overall Survival of Patients With OSCC
Univariable Analysis Multivariable Analysis
HR (95% CI) P HR (95% CI) P
Age 0.97 (0.94–1.00) 0.08
Gender
Male 1 0.43
Female 0.62 (0.18–2.05)
Tobacco Habits
No 1 0.16
User/former user 4.20 (0.56–31.19)
Pack/years 1.01 (0.99–1.03) 0.17
Pain
No 1 0.01
Yes 6.13 (1.44–26.08)
Size
T1/T2 1 0.003
T3/T4 5.99 (1.80–19.93)
Nodal metastasis
Absent 1 0.67
Present 1.17 (0.55–2.47)
TNM
I/II 1 0.003 1 0.01
III/IV 9.13 (2.16–38.56) 4.97 (1.45–16.98)
Recurrence
No 1 0.02 1 0.04
Yes 2.33 (1.14–4.76) 2.50 (1.03–6.08)
Histopathologic graduation
Grade I 1 0.02
Grade II/III 3.30 (1–5.07)
hMSH2 1.01 (0.98–1.03) 0.41
hMSH6 1.01 (1.00–1.03) 0.03
MutSa expression
Low 1 0.03 1 0.02
High 2.27 (1.04–4.97) 2.75 (1.13–6.65)
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Medicine  Volume 95, Number 22, June 2016 MutSa Complex in Oral Squamous Cell CarcinomaACKNOWLEDGMENTS
The authors are grateful to Flavia Rejane Giusti for her
technical support and the Biostatistics Unit of the Postgraduate
Research Group of the Porto Alegre University Hospital for
performing the statistical analysis.
REFERENCES
1. Mascolo M, Siano M, Ilardi G, et al. Epigenetic disregulation in oral
cancer. Int J Mol Sci. 2012;13:2331–2353.
2. Li GM. Mechanisms and functions of DNA mismatch repair. Cell
Res. 2008;18:85–98.
3. Stark AM, Doukas A, Hugo HH, et al. Expression of DNA mismatch
repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Neurol Res. 2015;37:95–105.
4. Edelbrock MA, Kaliyaperumal S, Williams KJ. Structural, molecular
and cellular functions of MSH2 and MSH6 during DNA mismatch
repair, damage signaling and other noncanonical activities. Mutat
Res. 2013:743–74453–66.
CI¼ confidence interval, HR¼ hazard ratio. HR and CI estimated by5. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic
recombination, and cancer biology. Annu Rev Biochem.
1996;65:101–133.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.6. Peltoma¨ki P. Role of DNA mismatch repair defects in the pathogen-
esis of human cancer. J Clin Oncol. 2003;21:1174–1179.
7. Uehara H, Miyamoto M, Kato K, et al. Deficiency of hMLH1 and
hMSH2 expression is a poor prognostic factor in esophageal
squamous cell carcinoma. J Surg Oncol. 2005;92:109–115.
8. Caldeira PC, Abreu MH, Batista AC, et al. hMLH1 immunoexpres-
sion is related to the degree of epithelial dysplasia in oral
leukoplakia. J Oral Pathol Med. 2011;40:153–159.
9. Jessri M, Dalley AJ, Farah CS. hMSH6: a potential diagnostic
marker for oral carcinoma in situ. J Clin Pathol. 2015;68:86–90.
10. Souza LR, Fonseca-Silva T, Pereira CS, et al. Immunohistochemical
analysis of p53, APE1, hMSH2 and ERCC1 proteins in actinic
cheilitis and lip squamous cell carcinoma. Histopathology.
2011;58:352–360.
11. Sarmento DJ, de Almeida WL, Miguel MC, et al. Immunohisto-
chemical analysis of mismatch proteins in carcinogenesis of the
lower lip. Histopathology. 2013;63:371–377.
x proportional hazard regression model.mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and
hMSH3, in squamous cell carcinoma of the head and neck. Oral
Oncol. 2003;39:115–129.
www.md-journal.com | 7
13. Demokan S, Suoglu Y, Demir D, et al. Microsatellite instability and
methylation of the DNA mismatch repair genes in head and neck
cancer. Ann Oncol. 2006;17:995–999.
14. Czerninski R, Krichevsky S, Ashhab Y, et al. Promoter hypermethy-
lation of mismatch repair genes, hMLH1 and hMSH2 in oral
squamous cell carcinoma. Oral Dis. 2009;15:206–213.
15. Fernandes AM, Ramos-Jorge ML, Cardoso SV, et al. Immunoexpres-
sion of hMSH2 and hMLH1 in oral squamous cell carcinoma and its
relationship to histological grades of malignancy. J Oral Pathol
Med. 2008;37:543–548.
16. Alvino E, Passarelli F, Cannavo` E, et al. High expression of the
mismatch repair protein MSH6 is associated with poor patient
survival in melanoma. Am J Clin Pathol. 2014;142:121–132.
17. Jentzsch T, Robl B, Husmann M, et al. Expression of MSH2 and
MSH6 on a tissue microarray in patients with osteosarcoma. Antic-
ancer Res. 2014;34:6961–6972.
18. Ting S, Mairinger FD, Hager T, et al. ERCC1, MLH1, MSH2,
MSH6, and (III-tubulin: resistance proteins associated with response
and outcome to platinum-based chemotherapy in malignant pleural
mesothelioma. Clin Lung Cancer. 2013;14:558–567e3.
19. Bryne M, Koppang HS, Lilleng R, et al. Malignancy grading of the
deep invasive margins of oral squamous cell carcinomas has high
prognostic value. J Pathol. 1992;166:375–381.
Wagner et alreliable method for immunohistochemical analysis of pleomorphic
adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:81–88.
8 | www.md-journal.com21. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on
the status of cancer, 1975-2001, with a special feature regarding
survival. Cancer. 2004;101:3–27.
22. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of
cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–
2917.
23. Kato M, Takano M, Miyamoto M, et al. DNA mismatch repair-
related protein loss as a prognostic factor in endometrial cancers. J
Gynecol Oncol. 2015;26:40–45.
24. Jascur T, Boland CR. Structure and function of the components of
the human DNA mismatch repair system. Int J Cancer.
2006;119:2030–2035.
25. Marra G, Chang CL, Laghi LA, et al. Expression of human MutS
homolog 2 (hMSH2) protein in resting and proliferating cells.
Oncogene. 1996;13:2189–2196.
26. Christmann M, Tomicic MT, Kaina B. Phosphorylation of mismatch
repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-
binding activity. Nucleic Acids Res. 2002;30:1959–1966.
27. Mardis ER. Next-generation DNA sequencing methods. Annu Rev
Genomics Hum Genet. 2008;9:387–402.
28. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of
head and neck squamous cell carcinoma reveals inactivating muta-
tions in NOTCH1. Science. 2011;333:1154–1157.
Medicine  Volume 95, Number 22, June 201629. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape20. Fonseca FP, de Andrade BA, Rangel AL, et al. Tissue microarray is aof head and neck squamous cell carcinoma. Science. 2011;333:1157–
1160.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
